~~<i id='CB44E0F20D'><strike id='CB44E0F20D'><tt id='CB44E0F20D'><pre id='CB44E0F20D'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

leisure time

author：fashion 2025-08-25 07:30:02 - browse：99818

An illustration of red blood cells — Adobe

As a boy growing up with hemophilia A, Noah Frederick reserved the end of his annual checkups to talk about new technologies. His doctor walked through various experimental approaches for the bleeding disorder and, invariably, gene therapy. It was coming, he always said, in your lifetime.

Last year, it finally arrived. But Frederick, now a 23-year-old software engineer, isn’t sure he’ll get it. He wants to be part of the sci-fi future gene therapy has always represented, but a recent doctor’s visit left him uncertain.

“I’m on the fence,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Colorectal cancer study finds potential in overlooked immune cell

entertainment

hotspot

entertainment

explore

focus

ThecorporateofficesofMassachusettsGeneralBrighamhospitalsinAssemblySquareinSomerville.LaneTurner/Glo

WSS

Bristol 'take

Data show record exodus of life scientists from academia

Sudafed saga points to U.S. issues with evaluating older drugs

Why do women spend more than men on medical expenses?

Medicaid, Medicare dual

Kaiser Permanente unions announce official strike date

entertainment

leisure time

entertainment

Duchenne breakthrough therapy leaves behind pioneering families

Was Amgen transparent enough on FDA's concern on cancer drug?

After affirmative action ruling, medical educators look to 'holistic review'

Would Medicare drug price negotiations stall in a shutdown?

Jerome Adams on the need for new antivirals for Covid

Menendez indictment could see pharma lose a key ally

ChatGPT in medicine: STAT answers readers' burning questions

Mindstrong's demise and the future of mental health care

Trump demands the U.S. pay no more for drugs than other countries … again

Phenylephrine and the overlooked value of the placebo effect

hotspot

Biogen shutters digital health group, ends Apple study, in cost cutting move

Menendez indictment could see pharma lose a key ally

FDA panel signals lack of confidence in Amgen cancer drug data

Analysis of telehealth claims data suggest service duplication

How the Dana

Senate panel eyes new effort on drug shortages

entertainment

explore

explore

focus